Abstract 5595: SGLT2 Inhibitors as a Novel Therapeutic Strategy for Diastolic Improvement and Survival in Hypertrophic Cardiomyopathy
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.5595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von khadeeja A Hamzah und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Hypertrophic cardiomyopathy (HCM) is characterized by impaired diastolic relaxation and an increased risk of heart failure and sudden cardiac death. While sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated benefits across various heart failure populations, their role in HCM remains uncertain. This meta-analysis aimed to evaluate the clinical and echocardiographic effects of SGLT2i therapy in patients with HCM.
Methods
A systematic search was conducted to identify studies comparing SGLT2i with standard care or placebo in patients with HCM, including randomized controlled trials and cohort studies. The primary outcome was all-cause mortality. Secondary outcomes included heart failure (HF) rehospitalization, E/e′ ratio (an echocardiographic marker of left ventricular filling pressure and diastolic dysfunction), and left ventricular ejection fraction (LVEF). Pooled risk ratios (RR) and mean differences (MD) were calculated using a random-effects model.
Results
A total of 4 studies (1 randomized controlled trial and 3 cohort studies) were included. Analysis of all-cause mortality involved 4,998 patients (2,499 in the SGLT2i group and 2,499 in the control group), with 151 events in the SGLT2i group and 432 in controls. SGLT2i therapy was associated with lower all-cause mortality (RR = 0.34, 95% CI [0.27-0.44], P < 0.00001; I 2 = 16%). For HF rehospitalization, 5,046 patients (2,523 in each group) were analyzed, showing a non-significant trend toward reduced risk with SGLT2i (RR = 0.73, 95% CI [0.53-1.01], P = 0.06; I 2 = 56%). Echocardiographic analysis of 236 patients demonstrated that SGLT2i therapy was associated with a reduction in E/e′ ratio (MD = -4.39, 95% CI [-5.50 to -3.28], P < 0.00001; I 2 = 32%), suggesting improvement in diastolic filling pressures. SGLT2i was also associated with a small reduction in LVEF (MD = -0.69, 95% CI [-1.37 to -0.02], P = 0.04; I 2 = 0%).
Conclusions
Among patients with HCM, SGLT2i therapy was associated with lower all-cause mortality and improved echocardiographic markers of diastolic function. Although the reduction in HF rehospitalization did not reach statistical significance, these findings suggest a potential role for SGLT2i in HCM management. Larger randomized studies are needed to confirm these observations.
Zitieren
APA
Hamzah, K. A., Kurmasha, Y., Hameed, A. A. Z., Almehanni, M., Abdulsalam, A. M., Sabah, A., Radhi, A., Alsaffar, Z., IMAD, H., Nayif, K., ALsaedi, M., & Alsaadany, K. R. (2026). Abstract 5595: SGLT2 Inhibitors as a Novel Therapeutic Strategy for Diastolic Improvement and Survival in Hypertrophic Cardiomyopathy. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.5595
Vancouver
Hamzah KA, Kurmasha Y, Hameed AAZ, Almehanni M, Abdulsalam AM, Sabah A, et al. Abstract 5595: SGLT2 Inhibitors as a Novel Therapeutic Strategy for Diastolic Improvement and Survival in Hypertrophic Cardiomyopathy. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.5595
BibTeX
@article{Hamzah2026,
author = {Hamzah, khadeeja A and Kurmasha, Yousif and Hameed, Al-Tuaama Abdullah Zeyad and Almehanni, Murtatha and Abdulsalam, Ameen M and Sabah, Abdullah and Radhi, Aya and Alsaffar, Zainab and IMAD, HAYDER and Nayif, Khattab and ALsaedi, Mojtaba.J.A and Alsaadany, Khalid Radwan},
title = {Abstract 5595: SGLT2 Inhibitors as a Novel Therapeutic Strategy for Diastolic Improvement and Survival in Hypertrophic Cardiomyopathy},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.5595}
}
EUVIMED